Issue #107

Inside: A deep dive into the AI-driven recovery of LendingTree and Alpha Cognition’s 20-year patent moat.

The financial landscape of 2026 isn’t being shaped by speculative bets or "moonshot" startups—it is being redefined by the companies that own the critical infrastructure of consumer trust and clinical necessity. As the economy balances on the edge of shifting interest rates and an aging global demographic, two sectors matter more than any others: the digital marketplaces that optimize household capital and the biotech innovators solving our most expensive healthcare crises.

This is where the financial conversation shifts from high-level macro trends to the essential services people cannot live without—and where the most resilient market leaders are separating themselves from the pack.

👉 One company has evolved from a mortgage marketplace into a diversified financial powerhouse, dominating the insurance and small business lending sectors through advanced AI integration.

👉 The other is a commercial-stage biotech disruptor that just launched a potential standard-of-care treatment for Alzheimer’s, backed by patent protection that stretches into the 2040s.

👉 Both have secured critical "Buy" ratings from analysts in the last 30 days and are successfully navigating the complexities of the current regulatory and interest rate environments.

In this edition, we break down the algorithm-driven marketplace and the neurological breakthrough at the center of the 2026 recovery—and why these two stocks represent the foundation of a modern, diversified portfolio.

LendingTree (NASDAQ: TREE)

LendingTree (NASDAQ: TREE) is a leading online financial services marketplace that connects consumers with a vast network of over 500 financial partners. By offering a platform where users can compare offers for mortgages, personal loans, credit cards, and insurance, LendingTree simplifies complex financial decisions. The company’s "North Star" strategy focuses on becoming the ultimate destination for financial shopping, leveraging a massive ecosystem of lenders and carriers to drive consumer savings and partner growth.

Business Model and Revenue Streams 📦

LendingTree operates a high-leverage marketplace model where it earns revenue primarily through referral and match fees. Rather than acting as a lender itself, it serves as a sophisticated lead-generation engine. The company’s revenue is diversified across three core segments:

• Insurance: Currently the company's powerhouse, this segment generates revenue from insurance carriers and agents who pay for consumer leads. In 2025, this became the dominant driver of growth, fueled by strong demand from auto and home insurance carriers looking to expand their policyholder bases.
• Consumer: This segment includes personal loans, credit cards, small business loans, and student loans. Revenue is earned when a consumer is matched with a lender or successfully applies for a product. Recently, small business lending has emerged as a high-growth sub-segment within this category.
• Home: This traditional core includes purchase mortgages, refinances, and home equity loans. LendingTree earns fees from mortgage lenders when consumers submit inquiries for home financing products.

The business model is highly sensitive to macroeconomic policies, particularly interest rate cycles set by the Federal Reserve. High interest rates typically suppress mortgage and refinance volumes, pressuring the Home segment. Conversely, in an environment where consumers feel "pinched," demand for debt consolidation and insurance shopping often increases. LendingTree has successfully navigated these shifts by pivoting its marketing focus toward the Insurance and Small Business sectors, which have proven more resilient to the "higher-for-longer" rate environment of 2025.

Recent Performance and Corporate Developments 📈

LendingTree reported its fourth-quarter and full-year 2025 results on March 2, 2026, revealing a business in the midst of a significant transformation.

Q4 2025 Financial Highlights: 💰

• Total Revenue: Revenue for the quarter reached $319.7 million, a 22.3% increase year-over-year, significantly beating analyst estimates. This was driven by a record performance in the Insurance segment.
• Net Profit: The company reported a GAAP net income of $144.7 million for Q4, though this was largely boosted by a one-time $146.4 million tax benefit. On an adjusted basis, the company saw continued strength in its operating leverage.
• Variable Marketing Margin (VMM): VMM, a key metric representing revenue minus marketing spend, was $92 million, reflecting efficient customer acquisition despite rising media costs.
• Segment Growth: The Insurance segment grew 20% in Q3 and remained the standout in Q4, while Small Business revenue within the Consumer segment surged by an impressive 78% year-over-year.

Strategic Initiatives and Mergers: 🤝

LendingTree has not engaged in major mergers recently, choosing instead to focus on internal "AI-enabled growth." The company has successfully integrated AI into its call center operations and customer funnels, which added over $10 million in quarterly revenue with minimal incremental expense. A notable corporate shift occurred in mid-2025 when the company exited its insurance agency business to focus entirely on its higher-margin marketplace model. Additionally, in March 2026, the company expressed strong support for the Homebuyers Privacy Protection Act, a move designed to improve the consumer experience by curbing abusive "trigger lead" practices in the mortgage industry.

Profitability and Fair Value 🎯

LendingTree has demonstrated a clear path to sustained profitability by focusing on high-margin segments and operational efficiency. The company’s Adjusted EBITDA grew by 28% in 2025, outpacing revenue growth and showcasing strong operating leverage.

In terms of fair value, LendingTree currently presents a compelling but volatile case. The stock's price-to-sales ratio sits at a modest 0.5x, significantly lower than many of its fintech peers, suggesting the market may be underestimating its recovery potential. While the P/E ratio has fluctuated due to one-time tax items and legal settlements, the company's focus on growing its free cash flow—which reached $28 million in a recent quarter—indicates a stabilizing financial foundation. Analysts suggest the stock may be undervalued as it transitions from a mortgage-heavy business to an insurance and AI-driven marketplace.

Analyst Estimates and Ratings 📊

• Consensus Rating: The consensus among analysts remains a "Buy." Over the last 30 days, the stock has maintained strong support, with 19 "Buy" ratings and only 2 "Hold" ratings.
• Price Target: The median 12-month price target is approximately $64.24, representing a significant upside from its current trading price of around $40.00. Some aggressive targets reach as high as $85.00, though some firms like Needham recently moderated their targets to $60.00 to account for broader market multiple compression.

Investor-Focused Takeaway: Is TREE Right for Your Portfolio?

LendingTree offers a play on the "rebound" of the American consumer. By successfully diversifying away from a pure reliance on the mortgage market, the company has insulated itself against interest rate volatility. The aggressive integration of AI and the explosive growth in the Insurance segment provide a solid runway for 2026.

What to Watch in the Near Term: 📈

• Insurance Partner Concentration: One major partner, Progressive, accounts for a significant portion of revenue. Any shift in their marketing spend could impact TREE's top line.
• Interest Rate Pivot: If the Fed begins a more aggressive rate-cutting cycle in late 2026, the Home segment could see a massive resurgence, acting as a secondary growth engine.
• AI Efficiency: Continue to monitor how AI-driven conversion improvements impact the Variable Marketing Margin.

Recommendation:

LendingTree (TREE) is a high-conviction "Buy" for investors seeking exposure to the fintech sector at a reasonable valuation. The company’s record-breaking insurance performance and disciplined cost management make it a strong candidate for a growth-oriented portfolio as it continues to take market share from legacy competitors.

Alpha Cognition (NASDAQ: ACOG)

Alpha Cognition (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company dedicated to developing novel therapies for neurodegenerative disorders. The company’s primary focus is on Alzheimer’s Disease (AD) and Cognitive Impairment associated with mild Traumatic Brain Injury (mTBI). Its flagship product, ZUNVEYL® (benzgalantamine), was FDA-approved in July 2024 and officially launched in the U.S. market in March 2025, marking a pivotal transition for the company from R&D to commercial operations.

Business Model and Revenue Streams 📦

Alpha Cognition operates on a high-growth biopharmaceutical model centered on the commercialization of its patented "prodrug" technology. Unlike traditional Alzheimer's treatments that often cause severe gastrointestinal (GI) distress, Alpha Cognition’s technology is designed to bypass the gut, potentially offering a more tolerable long-term solution. The company’s revenue is generated through two primary channels:

• Direct Product Sales: Following its 2025 launch, the company generates revenue through the sale of ZUNVEYL, specifically targeting the $2 billion long-term care (LTC) and nursing home market in the U.S.
• Licensing and Royalties: Alpha Cognition aggressively pursues global expansion through strategic partnerships. A landmark $44 million deal with CMS Pharma for the Greater China market provided an immediate $3 million upfront payment in early 2025, with recurring royalty streams expected to begin in late 2026.

Macroeconomic policies and the regulatory environment significantly influence the company’s trajectory. While inflation can impact R&D costs, the primary macro driver for ACOG is the U.S. healthcare reimbursement landscape. The company’s ability to secure Medicare coverage shortly after launch was a critical win, as the elderly population—most affected by Alzheimer's—relies heavily on government-funded insurance. Furthermore, the high-interest-rate environment of 2025 made capital raises more expensive, but the company successfully navigated this by securing a $35 million oversubscribed public offering to fund its commercial runway.

Recent Performance and Corporate Developments 📈

The company is currently in a rapid "ramp-up" phase. Management is scheduled to report full-year 2025 results on March 26, 2026, but recent quarterly data highlights significant momentum.

Recent Financial and Operating Highlights: 💰

• Commercial Traction: In its first full quarter of sales (Q3 2025), the company reported $2.8 million in total revenue, with $2.3 million coming directly from ZUNVEYL product sales.
• Market Adoption: As of late 2025, the company had engaged over 2,000 nursing homes, with a high "reorder rate" of 70%, signaling strong clinical acceptance of the drug's tolerability profile.
• Clinical Expansion: In February 2026, Alpha Cognition enrolled the first patient in its BEACON study, a Phase 4 real-world effectiveness trial. This study is vital for providing the "real-world" data that neurologists and payers require to shift prescriptions away from legacy generic competitors.
• Patent Protection: The company recently secured a new U.S. patent that extends ZUNVEYL’s protection through 2044, a massive "moat" that protects long-term cash flows from generic competition.

Profitability and Fair Value 🎯

Alpha Cognition is currently in the "investment phase" of its lifecycle and is not yet profitable. For the full year 2024, it reported a net loss of $14.6 million, and while revenues are now growing, the heavy costs of a national sales force and Phase 4 trials mean the company is prioritizing market share over immediate net income.

Regarding Fair Value, the stock presents a classic high-risk, high-reward biotech profile.

• Cash Runway: With approximately $48 million in cash at the start of 2025 and subsequent raises, the company estimates it has enough capital to reach 2027.
• Valuation: Trading around $5.75 to $6.00 in March 2026, some analysts view the stock as significantly undervalued relative to the peak sales potential of ZUNVEYL. However, third-party valuation models (like AAII) caution that the stock is "expensive" on a current-earnings basis because those earnings are still negative.

Analyst Estimates and Ratings 📊

• Consensus Rating: The stock currently holds a "Strong Buy" consensus among the analysts covering it.
• Price Target: H.C. Wainwright recently reiterated a "Buy" rating with a price target of $18.00, suggesting an upside of over 200% from current levels.
• Market Sentiment: Investors are closely watching the March 26, 2026, earnings call for updated 2026 revenue guidance. The "bull case" rests on the drug's expansion into neurologists' offices outside of the long-term care setting.

Investor-Focused Takeaway: Is ACOG Right for Your Portfolio?

Alpha Cognition is a "pure-play" on the next generation of Alzheimer's care. If ZUNVEYL becomes the standard of care due to its superior tolerability, the current market cap will look like a bargain. However, investors must be comfortable with the volatility inherent in small-cap biotech.

What to Watch in the Near Term: 📈

• China Regulatory Progress: Updates on the 2026 approval timeline in China could trigger significant milestone payments.
• Second PBM Contract: Securing a second major Pharmacy Benefit Manager (PBM) contract would dramatically increase the "available market" for ZUNVEYL.
• BEACON Study Data: Early readouts from real-world usage will be the primary catalyst for long-term institutional investment.

Recommendation:

Alpha Cognition (ACOG) is a compelling speculative "Buy" for those looking to capitalize on the aging global demographic. With a clear regulatory path, a launched product, and protection until 2044, it is one of the more de-risked small-cap biotechs on the market today.

Final Take: The Consumer Marketplace and the Clinical Breakthrough

The current market isn’t rewarding speculation—it’s rewarding utility and resilience. Whether it’s a household optimizing its budget or a family seeking the next generation of dementia care, value is being created by the platforms that solve essential problems at scale.

That’s where LendingTree (TREE) and Alpha Cognition (ACOG) stand apart.

🏡 LendingTree (TREE) — The Financial Ecosystem for the Modern Consumer

• ✔ Pivot to Resilience: Successfully shifted focus from a volatile mortgage market to a record-breaking Insurance segment (up 25% YoY).
• ✔ Efficiency at Scale: Leveraging AI to drive massive growth in Small Business lending (+78%) while maintaining tight operating leverage.
• ✔ Strengthening Balance Sheet: Net leverage declined significantly in 2025, providing a stable foundation for a 2026 growth breakout.
• ➤ Best for: Investors seeking a high-upside financial recovery play that is successfully using technology to capture market share from legacy competitors.

💊 Alpha Cognition (ACOG) — The Biopharma Innovator with a 20-Year Moat

• ✔ Commercial Launch: ZUNVEYL® is now in the hands of patients, targeting a $2B high-volume long-term care market with superior tolerability.
• ✔ Global Expansion: Secured high-margin licensing deals in Asia and is tracking toward multiple international approvals in 2026.
• ✔ Long-Term Protection: Recently secured patent protection until 2044, insulating its revenue from generic competition for decades.
• ➤ Best for: Investors looking for a de-risked biopharmaceutical play with a clear path to operating profitability by 2027 and a massive analyst-backed price target.

Investor Insight

🧩 Want a diversified financial marketplace with AI-driven efficiency? → TREE

⚙️ Want a high-moat clinical breakthrough with global royalty potential? → ACOG

Bottom Line:

Market leadership in 2026 belongs to the companies that own their niche through either digital dominance or proprietary science. LendingTree owns the "North Star" of financial shopping, while Alpha Cognition owns a generation-defining neurodegenerative treatment. As the year progresses, these aren’t just stocks to watch—they are foundational pieces of a sector-diversified growth strategy.

​
Happy Trading
​— Team Premium Stock Alerts